Share on LinkedInShare on LinkedIn

ARTICLE · 10 FEBRUARY 2023

Competition Law Developments In The Pharma Sector – 2022 Round-up And What To Expect In 2023

In this update, our competition law experts consider a number of recent competition law developments in the pharma sector in the EU, France, Germany, Spain, the UK and China.

GlobalAntitrust/Competition Law

In this update, our competition law experts consider a number of recent competition law developments in the pharma sector in the EU, France, Germany, Spain, the UK and China. This is a selective list of developments that may have practical implications on the way pharma companies carry on their business. Please feel free to get in touch with one of the authors or with your usual HSF contact if you would like to discuss any of these developments in more detail.

EU

As anticipated in our update last year, we have continued to see a number of important developments relevant to the pharmaceutical sector during the course of 2022. The European Commission (EC) continues to target the sector as one of its enforcement priorities, especially when it comes to protecting innovation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from